In its second quarter earnings release, Junshi Biosciences announced that its product candidate JS016 was approved to conduct a Phase 1 clinical trial in China. The trial is a randomized, double-blind, placebo-controlled study to evaluate the tolerability and safety of single-dose intravenous infusion of JS106 in healthy subjects. According to…
The COVID-19 pandemic has introduced new challenges for the pharmaceutical industry, including makers of biosimilars. In response, the FDA has asked pharmaceutical makers to closely monitor their supply chains and highlighted some of the ways the coronavirus could impact developmental pipelines. While the risk of supply chain disruptions is uncertain,…